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MHC class I molecules present cytosolic pep-
tides to class I–restricted CTLs. Shortly after 
their generation in the cytosol, peptides are 
translocated to the lumen of the ER by the 
transporter of antigen presentation (TAP) pep-
tide transporter and loaded onto peptide-recep-
tive MHC class I complexes with the assistance 
of a variety of chaperones, including calreticulin, 
ERp57, and Tapasin (1–4). Stably conformed 
and peptide-fi  lled class I complexes then egress 
from the ER to the cell surface for recognition 
by CD8+ T cells.
Most MHC class I allomorphs require 
peptides that are 8–10 amino acids in length 
for their stable assembly in the ER and trans-
port to the cell surface (5). Therefore, cells 
must be capable of degrading the vast major-
ity of intracellular proteins into peptides that 
meet this strict length requirement. Protea-
somes appear to be responsible for the initial 
proteolytic attack of most proteins and defec-
tive translation products that are degraded in 
the cytosol (6–9). Purifi   ed proteasomes can 
generate peptides that are between 2 and 
25 amino acids in length, but only  15% 
of these peptides are of the correct size for 
optimal class I binding (10, 11). Although it 
has been well established that proteasomes are 
responsible for generating the fi  nal  COOH 
terminus of peptide epitopes, they typically 
generate peptides with NH2-terminal exten-
sions (12). This tendency for generating pre-
cursors with NH2-terminal extensions may be 
enhanced for a version of the proteasome, 
termed the immunoproteasome, containing 
catalytic subunits that are induced by IFN-γ 
(11, 12). These findings suggested that many 
peptides generated by the proteasome need to 
be trimmed, either before or after transport 
to the ER lumen, to the optimal length for 
binding with class I molecules. Recent studies 
have provided evidence for a role of both cy-
toplasmic and ER-resident proteases in trim-
ming peptide precursors (9, 13, 14). Emerging 
evidence indicates that relatively long protea-
some products (>15 amino acids in length) 
are shortened in the cytosol by the NH2-ter-
minal exopeptidase tripeptidyl peptidase II 
and that peptides with relatively short NH2-
terminal extensions may be further trimmed 
by cytosolic aminopeptidases and endopepti-
dases (13, 14). Although cytosolic peptidases 
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trim a substantial proportion of precursor peptides to the 
correct size for binding with class I, many peptides enter the 
ER lumen with NH2-terminal extensions (15). This may be 
caused, at least in part, by the preference of TAP to translo-
cate peptides between 8 and 16 amino acids in length (16). 
Although evidence for NH2-terminal peptidase activity in 
the ER has been available for more than a decade (17, 18), 
the peptidases involved have eluded identifi  cation until re-
cently (19–22). ER-associated aminopeptidase (ERAP)1, 
also called ER aminopeptidase associated with antigen pro-
cessing, is a ubiquitous, IFN-γ–inducible metallopeptidase 
that catalyzes the sequential removal of diverse NH2-ter-
minal residues from peptide precursors (19–22). A second 
ER-resident, IFN-γ–regulated aminopeptidase, ERAP2, 
with more restricted tissue distribution, has been identifi  ed 
in humans but appears to be absent in rodents (22).
Apart from its inability to cleave the X-Pro (X denotes 
any amino acid) peptide bond, ERAP1 appears to have rela-
tively little sequence selectivity (19, 22, 23). However, one 
striking and unique feature of ERAP1 is that it effi   ciently 
trims NH2 terminally extended peptides but spares most pep-
tides that are eight amino acid residues or shorter (20, 21, 24), 
suggesting that ERAP1 favors the generation of peptides that 
are of the optimal size for binding with class I. Nevertheless, 
in some cases, recombinant ERAP1 destroyed cognate pep-
tide epitopes (20, 21). Consistent with these fi  ndings, reduc-
tion of ERAP1 expression by RNA interference resulted in 
defective presentation of several peptide epitopes (19, 21, 22) 
but did not aff  ect or even enhance presentation of some other 
epitopes (19). Moreover, whether ERAP1 expression infl  u-
ences the levels of class I molecules displayed at the cell sur-
face remains controversial. ERAP1 gene silencing in murine 
cells resulted in a reduction in the surface expression of H-
2Kk and H-2Ld molecules (19), whereas ERAP1 silencing in 
human HeLa cells or ERAP1 overexpression in monkey 
COS cells had no eff  ect on H-2Kb cell surface expression 
(21). One group reported that ERAP1 silencing in HeLa cells 
resulted in an increase in HLA-A, HLA-B, and HLA-C sur-
face expression (21), whereas another group found a modest 
reduction in HLA class I surface expression (22). The eff  ects 
of ERAP1 silencing on the IFN-γ–induced expression of 
class I molecules are also controversial (21, 22).
The cell lines that have been used to study ERAP1 func-
tion likely express nonphysiological levels of antigen-process-
ing factors that may impact the interpretation of the results 
obtained. For example, diff  erences in the expression levels of 
ERAP2 among distinct HeLa cell lines have been observed 
(9). In addition, studies with RNA interference have intrin-
sic drawbacks that may complicate data interpretation (25). 
Moreover, cell lines do not permit analysis of ERAP1 func-
tion by professional APCs or to determine its role in the gen-
eration of CTL responses in vivo. As an   approach to clarify 
these issues, we generated a mouse strain with a targeted dis-
ruption in the ERAP1 gene. Analysis of these animals indi-
cated defects in the surface expression of class Ia and class Ib 
molecules, class I–restricted antigen   presentation, and the 
generation of CTL responses. These fi  ndings reveal an im-
portant in vivo role of ERAP1 in optimizing peptides for 
surface display by MHC class I molecules.
RESULTS
Generation of ERAP1 mutant mice
ERAP1-defi  cient mice were generated by replacing a 600-
bp fragment of the ERAP1 gene, containing the sequence 
encoding the putative active site of ERAP1, with a neo-
mycin resistance cassette (Fig. 1, A–C). [ID]FIG1[/ID] Absence of ERAP1 
mRNA and protein in the mutant mice was confi  rmed by 
RT-PCR analysis (Fig. 1 D) and immunoblotting (Fig. 1 E), 
respectively. Because ERAP1 has been suggested to par-
ticipate in several functions unrelated to antigen process-
ing (26–28), we evaluated mice for obvious   abnormalities. 
However, mice appeared healthy, were fertile, and we 
were unable to detect any obvious anatomical or develop  -
mental defects.
Impact of ERAP1 defi  ciency on class I 
cell surface expression
To evaluate the eff  ects of ERAP1 defi  ciency on steady-state 
levels of MHC class I cell surface expression, we stained cells 
from wild-type and mutant animals with class I–specifi  c anti-
bodies. We found a reproducible reduction in the surface 
expression of H-2Kb and H-2Db molecules on total mono-
nuclear cells in the spleen, lymph node, and blood; on splenic 
DCs, T cells, and B cells (Fig. 2, A–C); and on fi  broblast 
cell lines derived from these animals (Fig. 2 F). [ID]FIG2[/ID] Levels of 
H-2Kb and H-2Db were reduced  40 and 50%, respectively. 
We also found a signifi  cant reduction in the extent of surface 
display of the nonclassical class I (class Ib) molecule Qa-2 
( 35% reduction as compared with wild-type cells; Fig. 2, 
A–C), which is ubiquitously expressed and binds with a wide 
array of nonameric peptides (29, 30).
IFN-γ induces the transcription of MHC class I genes 
and a variety of antigen processing–related genes, includ-
ing ERAP1 (13). Therefore, we measured class I levels on 
splenocytes and fi  broblasts after treatment with IFN-γ. The 
results indicated similar but less pronounced diff  erences in 
class I expression than those observed during steady-state 
conditions (Fig. 2, E and F). In fact, treatment of ERAP1−/− 
  fi  broblasts with IFN-γ for 5 d resulted in a profound increase 
in class I surface expression, reaching levels that were only 
slightly lower than those observed on similarly treated fi  bro-
blasts from ERAP1+/+ mice (Fig. 2 F).
We also evaluated class I expression by Con A–activated 
spleen lymphoblasts, which showed less profound diff  er-
ences in class I surface expression between ERAP1−/− and 
ERAP1+/+ cells than those observed during steady-state con-
ditions (Fig. 2, A and D). Interestingly, however, the extent 
of surface display of another ubiquitously expressed class Ib 
molecule, Qa-1b, which binds with a highly restricted set 
of nonameric peptides (31), was enhanced on lymphoblasts 
derived from ERAP1 mutant mice ( 30% increase as com-
pared with wild-type cells; Fig. 2, A and D).JEM VOL. 203, March 20, 2006  649
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During these experiments we noted that heterozygous 
mutant animals expressed class I surface levels that were inter-
mediate between wild-type littermates and homozygous mu-
tant littermates (Fig. 2). These results suggested that ERAP1 
expression levels in the ER are rate limiting for the genera-
tion of class I–binding peptides, at least in the absence of in-
fection or IFN-γ production.
Class I maturation and stability
Next, we determined whether ERAP1 defi  ciency was asso-
ciated with alterations in class I maturation and/or stability. 
The rate of transport of class I molecules from the ER to the 
cell surface can be estimated by the sensitivity of these mole-
cules to attack by endoglycosidase H (Endo H), which cleaves 
sugar moieties from class I heavy chains before, but not after, 
glycan modifi  cations in the medial Golgi apparatus. Pulse-
chase experiments with spleen lymphoblasts from ERAP1−/− 
and ERAP1+/+ mice revealed comparable acquisition of 
Endo H resistance by Kb and Db heavy chains, whereas class 
I heavy chains from control TAP1−/− cells, expressing class I 
molecules that are largely retained within the ER (32), were 
profoundly defective in the acquisition of Endo H resistance 
(Fig. 3, A and B). [ID]FIG3[/ID]
We evaluated the stability of class I heterodimers by incu-
bating cell extracts prepared from metabolically labeled spleen 
lymphoblasts at diff  erent temperatures, followed by immu-
noprecipitation with conformation-dependent anti-Kb and 
-Db antibodies. The results showed no detectable diff  erences 
in this parameter between cells from ERAP1−/−, ERAP1+/−, 
and ERAP1+/+ mice (Fig. 3, C and D).
As an additional measurement of class I stability, we 
treated splenocytes with brefeldin A to prevent transport of 
newly assembled class I complexes to the cell surface and 
determined the decay of H-2Kb and H-2Db molecules with 
conformation-dependent antibodies. The results showed 
a signifi  cant increase in the decay of both surface Kb and 
Db molecules from ERAP1−/− cells as compared with 
ERAP1+/+ cells (Fig. 3 E). Nevertheless, the accelerated de-
cay of class I molecules on ERAP1−/− cells was substantially 
less pronounced than on Tapasin−/− cells (Fig. 3 E), which 
express class I molecules that are predominantly loaded with 
low-affi   nity peptides (33–35).
Figure 1.  Generation of ERAP1 mutant mice. (A) The ERAP1 locus 
and targeting construct. Part of the wild-type ERAP1 gene is shown, 
along with the targeting construct, the mutated ERAP1 locus, and hybrid-
ization probes. Solid boxes indicate the exons of ERAP1. A 0.6-kb frag-
ment, which contains the sequence encoding the Zinc-binding motif of 
the putative active site of ERAP1, was deleted and replaced with a neo-
mycin resistance cassewwtte (Neo). The vector also contains a thymidine 
kinase (TK) cassette. ERAP1 5′- and 3′-fl  anking probes used for the 
screening of ES cell clones and mice are indicated, together with the ex-
pected sizes of the hybridizing restriction fragments in wild-type and 
mutant ERAP1 alleles. (B and C) Southern blot analysis of DNA from rep-
resentative ES cell clones and mice. Genomic DNA was isolated from ES 
cell clones (B) and mouse tails (C) with the indicated genotype. DNA was 
digested with EcoRV and hybridized with the 5′ or 3′ probe (see A). 
(D) RT-PCR amplifi  cation of ERAP1 transcripts. Total RNA was isolated from 
the spleen cells of the indicated mice, reverse-transcribed, and amplifi  ed 
with ERAP1-specifi  c primers. Genomic DNA (G) and water (N) were used 
as controls for DNA contamination and false positive amplifi  cation, re-
spectively. β-actin mRNA amplifi  cation was used as a positive control. 
(E) Western blot analysis of ERAP1 expression. ER proteins isolated from 
the liver of the indicated mice were separated by SDS-PAGE and probed 
with anti-ERAP1 or anti-gp96 antiserum.650  ERAP1 MUTANT MICE | Yan et al.
Defective presentation of self-antigens
To determine the eff  ects of ERAP1 defi  ciency on the presen-
tation of self-antigens to class I–restricted CTLs, we evaluated 
the capacity of a panel of minor histocompatibility (H) anti-
gen-specifi  c CTL clones to react with splenocytes from wild-
type and mutant animals. Because several of these CTLs 
recognize minor H antigens expressed in mice from the 129 
but not C57BL/6 strain (36–38), in these experiments, we 
used mutant and wild-type animals on a homogeneous 129 
strain–derived background (see Materials and methods).  Results 
Figure 2.  MHC class I cell surface expression. (A) Splenocytes, 
splenic DCs (B220−CD11chi), or Con A–activated spleen lymphoblasts from 
the indicated mice were stained with antibodies directed against MHC 
class Ia (H-2Kb and H-2Db) or class Ib (Qa-2 and Qa-1b) molecules and 
analyzed by fl  ow cytometry. (B–D) Summary of class I surface staining 
data. MHC class Ia and class Ib expression levels were analyzed on total 
mononuclear cells (MNC) from the spleen, blood, and lymph nodes (B), on 
splenic T cells, B cells, and DCs (C), or on Con A–activated spleen lympho-
blasts (D). Results in B and C indicate the mean ± SE of fi  ve mice and 
results in D indicate the mean ± SE of three mice. *, P < 0.05. (E and F) 
IFN-γ–induced class I expression. (E) Spleen cells from the indicated mice 
were cultured with or without 15 ng/ml IFN-γ for 16 h, followed by stain-
ing with class I–specifi  c antibodies and fl  ow cytometry. One representa-
tive experiment of three is shown. (F) Ear fi  broblast cell lines from the 
indicated mice were cultured with or without 15 ng/ml IFN-γ for 5 d, 
stained with class I–specifi  c antibodies, and analyzed by fl  ow cytometry.JEM VOL. 203, March 20, 2006  651
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showed a profound defect in the reactivity of two H60-specifi  c 
CTL clones and of an HY-specifi  c clone with 129.ERAP1−/− 
cells, whereas the two H4b-specifi  c clones reacted similarly 
with 129.ERAP1−/− and 129.ERAP1+/+ cells, and an H13b-
specifi  c clone reacted more strongly with 129.ERAP1−/− than 
129.ERAP1+/+ cells (Fig. 4 A).[ID]FIG4[/ID] None of these clones reacted 
with cells from female C57BL/6 mice, whereas another clone, 
specifi  c for the H4a antigen, which is expressed in mice from 
the C57BL/6 but not 129 strain, reacted with cells from 
C57BL/6 mice but not with cells from 129.ERAP1−/− or 
129.ERAP1+/+ mice (Fig. 4 A). These fi  ndings indicated that 
ERAP1 expression can have a positive, neutral, or negative 
  eff  ect on antigen presentation.
We also investigated the capacity of a panel of Qa-1b–re-
stricted, alloreactive CTL clones to lyse spleen lymphoblasts 
from mutant animals. The results revealed modest but signifi  -
cantly reduced capacity of each of these clones to lyse mutant 
cells as compared with wild-type cells (Fig. 4 B). Subtle but 
reproducible diff  erences in the extent of lysis of mutant cells, 
compared with wild-type cells, by distinct clones were ob-
served, which is likely due to diff  erences in the precise pep-
tide selectivity of individual clones.
Figure 3.  MHC class I maturation and thermostability. (A and B) 
Class I maturation. Con A blasts from the indicated mice were pulse-labeled 
with [35S]methionine/cysteine for 10 min and chased at 37°C for the indi-
cated times. Cell aliquots were lysed in NP-40 buffer. Class I molecules were 
precipitated with conformation-dependent antibodies (Y3 for H-2Kb and 
B22.249 for H-2Db). Immunoprecipitates were treated with Endo H, re-
solved by SDS-PAGE, and developed by phosphorimaging (A). Endo Hr and 
Endo Hs forms of MHC class I are indicated. The band intensities of the 
Endo Hr forms of MHC class I glycoproteins were quantifi  ed by ImageQuant 
software. The relative amounts of mature MHC class I complexes are shown 
as mean absolute intensities of each band normalized against that of the 
Endo Hs band at time 0 in each experiment (B). One representative experi-
ment of fi  ve is shown. (C and D) Class I thermostability in cell extracts. Con 
A blasts from the indicated mice were pulse-labeled with [35S]methionine/
cysteine for 1 h and chased at 37°C for 2 h. Cells were lysed in NP-40 buf-
fer, aliquoted, and incubated at the indicated temperatures for 1 h. Class I 
molecules were precipitated with conformation-dependent anti–H-2Kb or 
anti–H-2Db antibodies, followed by SDS-PAGE and phosphorimaging (C). 
The band intensities of Endo Hr and Endo Hs forms of MHC class I glycopro-
teins were quantifi  ed by ImageQuant software. Band intensities are shown 
as percent recovery of MHC class I complexes at different temperatures as 
compared with 4°C (D). One representative experiment of fi  ve is shown. 
(E) Thermostability of surface class I molecules. Splenocytes from ERAP1−/−, 
ERAP1+/+, and Tapasin−/− (TPN−/−) mice were cultured at 37°C with 
brefeldin A (BFA) for the indicated time intervals and then stained with 
conformation-dependent anti–H-2Kb and anti–H-2Db antibodies followed 
by fl  ow cytometry. Results are presented as percent recovery of MHC class I 
expression at different time points as compared with the 0 time point. 
Results shown represent data for three ERAP1−/− mice, three ERAP1+/+ 
mice, and one Tapasin−/− mouse. *, P < 0.05; **, P < 0.01.652  ERAP1 MUTANT MICE | Yan et al.
Defective presentation of foreign antigens
To investigate the impact of ERAP1 defi  ciency on the pre-
sentation of foreign antigens, we studied the capacity of mu-
tant cells to display the immunodominant OVA-derived CTL 
epitope (OVA257–264), after osmotic shock-mediated introduc-
tion of the native protein into the cytoplasm of cells, by 
H-2Kb molecules at the cell surface. H-2Kb/OVA257–264 
complexes were detected with an antibody that specifi  cally 
reacts with this particular class I–peptide complex. Results 
demonstrated a profound defect of ERAP1 mutant cells in 
displaying Kb/OVA257–264 complexes at the surface (Fig. 5 A). [ID]FIG5[/ID] 
Staining levels of OVA-loaded ERAP1−/− cells were only 
slightly higher than OVA-loaded TAP1−/− cells, indicating a 
strict requirement of ERAP1 for generating this epitope, 
which is consistent with prior reports (19–21). Similarly, bone 
marrow–derived DCs and LPS-induced lymphoblasts from 
ERAP1−/− mice were defective in presenting OVA, intro-
duced into these cells by osmotic shock, to an OVA257–264-
specifi  c, H-2Kb–restricted T cell hybridoma (Fig. 5 B). 
Strikingly, cells from heterozygous mutant animals also exhib-
ited profound defects in processing OVA for surface display 
by Kb (Fig. 5, A and B). Macrophages from mutant animals, 
  infected with an OVA-expressing strain of Listeria mono-
cytogenes, were also defective in presenting OVA antigens to 
OVA257–264-specifi  c T cells, but cells from heterozygous mu-
tants behaved more similarly to cells from wild-type animals in 
this assay (Fig. 5 C).
We also tested the capacity of splenic DCs from mutant 
animals to cross-present OVA antigens, adsorbed to latex 
beads, to OVA257–264-specifi  c T cells. The results revealed a 
profound defect of ERAP1−/− DCs in cross-presenting OVA 
antigens (Fig. 5 D).
Figure 4.  Presentation of self-antigens to class I–restricted CTLs. 
(A) Presentation of minor H antigens. The indicated numbers of spleen cells from 
male 129.ERAP1+/+ mice, male 129.ERAP1−/− mice, and female C57BL/6 
mice were used to stimulate the indicated minor H antigen–specifi  c CTL 
clones for 6 h. CTL activation was evaluated by detection of intracellular IFN-γ 
among CD8+ T cells. Data are plotted as the percentage of CD8+IFN-γ+ cells 
and normalized to the response to ERAP1+/+ splenocytes. The class I allele 
and minor H specifi  city of individual CTL clones, together with the identity of 
their cognate peptide epitope (underlined) and a few NH2-terminal fl  anking 
residues, are shown. Results are representative of fi  ve independent experi-
ments for each clone. (B) Antigen presentation to alloreactive Qa-1b–re-
stricted CTLs. Con A blasts from the indicated mice were used as targets for 
the indicated Qa-1b–restricted alloreactive CTL clones. TAP1−/− cells, pulsed 
with Qdm peptide, were used as a positive control. Results represent the 
mean from triplicate cultures at an effector–target ratio of 5:1. Results are 
representative of at least two independent experiments for each clone.JEM VOL. 203, March 20, 2006  653
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Finally, we infected DCs from wild-type and mutant ani-
mals with the lymphocytic choriomeningitis virus (LCMV) 
to compare the capacity of these cells to present the immu-
nodominant glycoprotein-derived gp33 epitope to H-2Db–
  restricted T cells. The results showed enhanced reactivity of 
the gp33-specifi  c T cells with ERAP1−/− than ERAP1+/+ 
cells (Fig. 5 E). These fi  ndings suggest that ERAP1 normally 
plays a role in destroying the LCMV gp33 epitope.
CD8+ T cell development
The surface levels of MHC class I molecules and the diver-
sity of peptides displayed by these molecules in the thymus 
can have a profound impact on both positive and negative 
selection of CD8+ T cells (39). Therefore, we examined 
CD8+ T cell development in ERAP1 mutant mice. Despite 
their   reduced levels in MHC class I cell surface expression, 
the prevalence and numbers of CD8+ T cells in ERAP1−/− 
mice were comparable to ERAP1+/+ mice (Fig. 6 A and 
not depicted). [ID]FIG6[/ID]
To determine whether ERAP1 defi  ciency infl  uences the 
positive selection of individual TCRs, we examined CD8+ T 
cell development in ERAP1−/− mice expressing a transgenic 
TCR (P14) specifi  c for the gp33 peptide epitope derived 
from the LCMV glycoprotein. These studies were performed 
with transgenic animals on a RAG2-defi  cient background to 
enhance our capacity to detect defects in the positive selec-
tion of transgenic T cells. However, the results failed to reveal 
diff  erences in the prevalence, numbers, or TCR expression 
levels among P14 TCR transgenic cells in ERAP1−/− versus 
ERAP1+/+ mice (Fig. 6 B and not depicted).
Figure 5.  Presentation of foreign antigens to class I–restricted 
CTLs. (A–D) Processing and presentation of endogenous and exogenous 
OVA antigens. (A) Bone marrow–derived DCs (BmDCs) from the indicated 
mice were loaded with OVA by osmotic shock. Cells were incubated at 
37°C for 0, 2, or 5 h and stained with the H-2Kb/SIINFEKL-specifi  c anti-
body 25-D1.16 or an isotype control antibody followed by fl  ow cytometry. 
SIINFEKL peptide-pulsed cells were used as a positive control. (B) Bone 
marrow–derived DCs or LPS-activated spleen lymphoblasts from the indi-
cated mice were loaded with OVA as in A and cocultured with B3Z hybrid-
oma cells overnight, followed by measurement of IL-2 in the supernatant. 
(C) Macrophages from the indicated mice were incubated in the absence 
or presence of OVA-expressing L. monocytogenes bacteria for 30 min and 
cultured with splenocytes from OT-1TgRAG1−/− mice for 24 h, and IL-2 
production was assessed. (D) Splenic DCs from the indicated mice were 
incubated with BSA- or OVA-coated latex beads and cultured with sple-
nocytes from OT-1TgRAG1−/− mice for 24 h, and IL-2 production was as-
sessed. (E) Presentation of the immunodominant LCMV gp33 CTL epitope. 
Splenic DCs from the indicated mice were infected with LCMV and cul-
tured with splenocytes from P14TgRAG2−/− mice for 24 h, and IL-2 pro-
duction was assessed.654  ERAP1 MUTANT MICE | Yan et al.
CD8+ T cell responses
Finally, we determined the impact of ERAP1 defi  ciency on 
the generation of CTL responses in vivo. We loaded spleno-
cytes from TAP1−/− mice ex vivo with OVA by osmotic 
shock and used these cells to immunize ERAP1−/− or 
ERAP1+/+ mice. 7 d later, mice were tested for the genera-
tion of OVA257–264-specifi  c CD8 T cell responses by stimu-
lating splenocytes with OVA257–264 and measuring the 
prevalence of IFN-γ–producing CD8+ T cells. The results 
showed a profound defect (three- to fourfold reduction) in 
the generation of OVA257–264-specifi  c CD8+ T cell responses 
in vivo (Fig. 7, A and B). [ID]FIG7[/ID]
We also determined the immune response of ERAP1−/− 
mice to infection by an infl  uenza virus. Mice were infected 
intranasally with the PR8 strain of infl  uenza virus and, 10 d 
later, lymph nodes from these animals were stimulated ex 
vivo with synthetic versions of a panel of H-2Kb– and H-
2Db–restricted peptide epitopes, and the prevalence of epit-
ope-specifi  c CD8 T cells in the cultures was evaluated by 
intracellular detection of IFN-γ. Our results revealed moder-
ately reduced responses in the generation of CTL responses 
directed against several of the immunodominant epitopes; 
nonetheless, the diff  erences did not reach statistical signifi  -
cance in any single experiment (Fig. 7, C and D).
DISCUSSION
Our fi   ndings have revealed an important in vivo role of 
ERAP1 in optimizing peptides for presentation by MHC 
class I molecules. Both H-2Kb and H-2Db bind with peptides 
that contain hydrophobic COOH-terminal amino acid resi-
dues, which represent preferred substrates for TAP (1, 2) and 
ERAP1 (24). In addition, both H-2Kb and H-2Db can bind 
with peptides that contain a proline residue in position 3, 
which are poorly translocated by the TAP peptide transporter 
(40) and, therefore, would likely be translocated as longer 
precursors. Consistent with these prior studies, we found that 
ERAP1 defi  ciency resulted in a signifi  cant reduction in the 
surface expression of H-2Kb and H-2Db. In addition to its ef-
fects on class Ia molecules, ERAP1 expression also infl  uenced 
surface expression of the class Ib molecules Qa-2 and Qa-1b. 
Consistent with prior studies (19, 21), we found that ERAP1 
expression can have a positive, neutral, or negative impact on 
the presentation of individual class I antigens. For several of 
the epitopes tested, including H60 (an 8-mer peptide pre-
sented by Kb), HY (a 9-mer peptide presented by Db), and 
OVA257–264 (an 8-mer peptide presented by Kb), ERAP1 
  expression appeared to play an important role, as presentation 
of these epitopes by ERAP1−/− cells, compared with 
ERAP1+/+ cells, was reduced 80–90%. These fi  ndings indi-
cate that cytosolic proteases are unable to compensate for 
ERAP1 defi  ciency in generating physiological levels of some 
epitopes. Because most minor H antigens and the epitopes 
recognized by alloreactive, Qa-1b–restricted CTLs are con-
stitutively expressed, cytosolic proteases should have suffi   -
cient opportunity to sample peptide precursors derived from 
these antigens that are recycled between the ER and the 
  cytosol (41, 42). Thus, we conclude that ERAP1 plays a rate-
limiting role in the generation of a sizeable subset of peptides 
for presentation by MHC class I molecules to CTLs. Consis-
tent with this conclusion, we found that ERAP1+/− mice 
exhibited a phenotype that, at least in some assays, was inter-
mediate between wild-type and mutant animals. Neverthe-
less, for some epitopes, ERAP1 expression had no eff  ect on 
antigen presentation (e.g., H4b) or instead suppressed antigen 
presentation (e.g., H13b and LCMV gp33).
Prior studies have provided confl  icting results regarding 
the role of ERAP1 in controlling MHC class I cell surface 
expression (19, 21, 22). ERAP1 knockdown by small inter-
fering RNA in murine L cells resulted in decreased expres-
sion of both H-2Kk and H-2Ld (19). Another group of 
Figure 6.  CD8+ T cell development. (A) Cells from the thymus, spleen, 
and peripheral blood of the indicated mice were stained with anti-CD4 
and anti-CD8 antibodies and analyzed by fl  ow cytometry. Numbers indi-
cate the percentage of cells within each quadrant. (B) Development of 
P14 transgenic T cells. ERAP1−/− animals were bred with RAG2-defi  cient 
P14Tg mice carrying a TCR specifi  c for the LCMV gp33 epitope presented 
by H-2Db. Cells from the thymus, spleen, and peripheral blood of 
P14TgERAP1−/−RAG2−/− and P14TgERAP1+/+RAG2−/− mice were stained 
with anti-CD8 and anti-Vα2 antibodies and analyzed by fl  ow cytometry. 
Numbers indicate the percentage of cells within the gated area.JEM VOL. 203, March 20, 2006  655
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investigators showed that ERAP1 knockdown in Kb-trans-
fected HeLa cells did not alter Kb surface expression but re-
sulted in an increase in HLA class I surface expression (21). 
Conversely, ERAP1 overexpression in H-2Kb–transfected 
COS cells did not aff  ect Kb surface expression but led to sig-
nifi  cant suppression of monkey class I expression (21). In 
sharp contrast with the latter studies, a third group of investi-
gators reported that ERAP1 knockdown in HeLa cells re-
sulted in a moderate decrease in HLA class I expression (22). 
We found that ERAP1 defi  ciency consistently led to a re-
duction in the steady-state levels of Kb, Db, and Qa-2 surface 
expression. These fi  ndings are consistent with prior studies 
evaluating the eff  ects of ERAP1 knockdown on class I ex-
pression in murine cells (19) but only partially agree with 
studies that have investigated the eff  ects of ERAP1 knock-
down or overexpression on H-2Kb expression in HeLa cells 
and COS cells, respectively (21).
Prior studies regarding the eff  ects of IFN-γ on class I sur-
face expression have also provided confl  icting results. One 
group of investigators reported that ERAP1 gene silencing in 
H-2Kb–transfected HeLa cells treated with IFN-γ resulted in 
signifi  cant suppression of both surface Kb and HLA expres-
sion (21). However, another group of investigators reported 
that ERAP1 silencing in IFN-γ–treated HeLa cells resulted 
only in a slight diminution in HLA class I expression, which 
was less evident than the decrease in class I expression caused 
by ERAP1 silencing in untreated cells (22). Consistent with 
the latter studies, we found that diff  erences in class I surface 
expression were less evident in splenocytes and fi  broblasts 
treated with IFN-γ and in Con A–activated T lymphocytes. 
Moreover, we found a slight but reproducible defect in the 
surface stability of Kb and Db molecules on nonstimulated 
splenocytes from ERAP1 mutant mice but were unable to 
detect defects in class I maturation or stability in ERAP1−/− 
Con A blasts. Collectively, our fi  ndings suggest that ERAP1 
plays a more important role in generating class I–binding pep-
tides during steady-state than during conditions where IFN-γ 
is produced. These fi  ndings were surprising because ERAP1 
expression itself is profoundly induced by IFN-γ (21). One 
possibility is that induction of ERAP1 expression during 
IFN-γ treatment results in increased epitope destruction 
compared with the levels of epitope destruction in the ab-
sence of IFN-γ. Nevertheless, our antigen presentation and 
immunization studies revealed a critical role of ERAP1 for 
presenting individual peptides to CD8+ T cells in both the 
absence and presence of IFN-γ production. Thus, ERAP1 
signifi  cantly impacts the presentation of individual peptides 
but has only relatively modest eff  ects on the overall capacity 
Figure 7.  CD8+ T cell responses. (A and B) CTL responses to OVA. The 
indicated mice were immunized with apoptotic splenocytes from TAP1−/− 
mice, loaded ex vivo with OVA by osmotic shock. 7 d later, spleen cells 
from these animals were stimulated with or without OVA257–264 peptide for 
6 h and IFN-γ–producing CD8+ T cells were detected by fl  ow cytometry. 
Representative fl  ow cytometry plots (A) and a summary of the percent 
IFN-γ+CD8+ cells (B) are shown for ERAP1+/+ and ERAP1−/− mice (n = 3 
per group). Numbers indicate the percentage of cells within the gated area. 
(C and D) CTL responses to infl  uenza virus. Mice were infected intranasally 
with the PR8 strain of infl  uenza virus. 10 d later, mediastinal lymph node 
cells of these animals were stimulated in the presence or absence of the 
indicated peptides for 6 h and IFN-γ–producing CD8+ T cells were de-
tected by fl  ow cytometry as described in Materials and methods. Repre-
sentative fl  ow cytometry plots (C) and a summary of the percent 
IFN-γ+CD8+ cells (D) are shown for ERAP1+/+ and ERAP1−/− mice (n = 4 
per group). Numbers indicate the percentage of cells within the gated area.656  ERAP1 MUTANT MICE | Yan et al.
of the generated peptide pool to stabilize class I molecules, 
particularly when IFN-γ is produced. This conclusion is con-
sistent with the idea that ERAP1 can both enhance and limit 
antigen presentation of individual peptide epitopes (21).
Although diff  erences between our studies and those of 
Serwold et al. (19) and Saveanu et al. (22) with the report by 
York et al. (21) remain unclear, it is possible that the immor-
talized cell lines used by the latter group of investigators 
expressed nonphysiological levels of antigen-processing mole-
cules. For example, diff  erences in the expression levels of 
human ERAP2 among the HeLa cell lines analyzed by 
Saveanu et al. and York et al. have been noted (9).
Our studies with Qa-2 and Qa-1b molecules provide the 
fi  rst direct evidence for a role of ERAP1 in generating pep-
tides for surface display by class Ib molecules. Qa-2 antigens 
are encoded by several class Ib genes and are either linked to 
the cell membrane via glycosylphosphatidylinositol anchors 
or secreted from cells (43). Qa-2 binds with a large array of 
nonameric peptides with a unique motif containing histidine 
at position 7 (29, 30, 44). Expression of both secreted and 
glycosylphosphatidylinositol-bound Qa-2 molecules is de-
pendent on a functional TAP peptide transporter (45), and 
we show here a role of ERAP1 for steady-state levels of Qa-2 
surface expression, suggesting that most peptides loaded onto 
Qa-2 molecules are generated via the conventional class Ia 
antigen-processing pathway. In sharp contrast with Qa-2, 
Qa-1b binds with a highly restricted set of nonameric peptides 
(31). Qa-1b predominantly binds with a single peptide, Qa-1 
determinant modifi   er (Qdm), derived from the leader se-
quence of other class I molecules (31, 46). Despite its localiza-
tion within a signal sequence, presentation of Qdm on Qa-1b 
is dependent on both TAP (47) and Tapasin (48). The pro-
duction of Qdm requires several antigen-processing events. 
After biosynthesis and entry of the nascent class I heavy chain 
into the ER, the signal sequence is cleaved by signal pepti-
dase. The resulting 24–amino acid Qdm peptide precursor, 
which is embedded in the membrane, is then cleaved by sig-
nal peptide peptidase, which allows the release of the NH2-
terminal peptide fragment into the cytosol. This fragment, 
M  G  A  M  A  P  R  T  L  L  L  L  L  A   (Qdm is underlined), is then pro-
cessed by cytosolic proteases to generate the fi  nal COOH 
terminus (current evidence suggests that the proteasome is 
not involved), resulting in a Qdm precursor containing a 
two–amino acid NH2-terminal extension (46). Here, we 
demonstrate that ERAP1 expression enhances the presenta-
tion of Qdm to Qdm-dependent, Qa-1b–restricted CTLs, 
suggesting that ERAP1 contributes to the removal of the two 
NH2-terminal amino acids of this peptide precursor. This 
conclusion is consistent with a prior study demonstrating that 
a Qdm precursor with a two–amino acid NH2-terminal ex-
tension can be processed to generate the Qdm epitope in the 
ER of TAP-defi  cient cells (49). However, we found that the 
reactivity of CTL clones with ERAP1-defi   cient cells was 
only partially diminished, suggesting that cytosolic amino-
peptidases can trim this Qdm peptide precursor as well, in a 
manner that is partially redundant with ERAP1. Neverthe-
less, it remains possible that during certain infections or in 
cancer cells, ERAP1 expression may represent a rate-limiting 
step in presenting Qdm peptides to Qa-1b–restricted CTLs or 
natural killer cells expressing CD94/NKG2 receptors.
Although our studies with Qdm indicate a critical role of 
ERAP1 for the processing of signal sequence–derived pep-
tide epitopes, they do not preclude the possibility that some 
signal sequences can be processed independently of ERAP1. 
Indeed, presentation of LCMV gp33, which is contained 
within the signal sequence of the viral glycoprotein (50), to 
gp33-specifi  c, Db-restricted T cells, was enhanced in ERAP1-
defi  cient cells, despite the requirement of TAP (51) and the 
proteasome (52) in the processing of this epitope. These fi  nd-
ings suggest that ERAP1 normally plays a role in destroying 
the LCMV gp33 epitope. In future studies, it will be interest-
ing to infect mutant mice with LCMV and determine the 
strength of the CD8+ T cell response directed against the 
gp33 and other LCMV epitopes.
A particularly surprising result of our studies was that, at 
least in some assays, ERAP1+/− mice exhibited a phenotype 
that was intermediate between ERAP1+/+ and ERAP1−/− 
mice. To our knowledge, this has not been described for any 
other mutations that aff  ect the class I antigen presentation 
pathway. However, an intermediate phenotype, at least with 
respect to some aspects of antigen presentation, has been de-
scribed for mice with a heterozygous mutation in the class II 
peptide exchange factor H-2DM (53). Thus, ERAP1 may 
play a rate-limiting role in the generation of a sizable subset of 
peptide epitopes. Although currently unclear, the diff  erential 
eff  ects of ERAP1 heterozygozity on the processing of indi-
vidual epitopes likely depends on the dose of the antigen, the 
method of antigen introduction, the length of antigen incuba-
tion with APC, and/or the sensitivity of the read-out assay.
In conclusion, our fi  ndings have revealed an important 
in vivo role of ERAP1 in controlling antigen presentation 
by both class Ia and class Ib molecules. We demonstrated 
that ERAP1 expression can have a positive, neutral, or neg-
ative contribution in the generation of individual class I 
  epitopes. Additional studies with these animals will be help-
ful in elucidating the role of ER-associated peptidase activ-
ity in the development of antiviral immune responses and in 
regulating the immunodominance hierarchy of CD8+ T cell 
responses in vivo.
MATERIALS AND METHODS
Mice. C57BL/6 mice were obtained from The Jackson Laboratory and 
129S6/SvEvTac mice were obtained from Taconic. TAP1-defi  cient mice 
(32) and Tapasin-defi  cient mice (33) have been described. P14TgRAG2−/− 
mice were obtained from Taconic and were bred with ERAP1 mutant mice 
to obtain P14TgERAP1−/−RAG2−/− and P14TgERAP1+/+RAG2−/− mice. 
OT-1Tg mice and RAG1−/− mice were obtained from The Jackson Labora-
tory and bred to obtain OT-1TgRAG1−/− mice. Mice were maintained in 
accordance with the Institutional Animal Care and Use Committee at Van-
derbilt University.
Generation of ERAP1 mutant mice. To establish an ERAP1 targeting 
construct, a 5.4-kb XhoI–ClaI fragment from the 5′ end of the ERAP1 
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the 3′ end of ERAP1 (from the 3′ end of exon 6 to exon 11) were ampli-
fi  ed from 129S6/SvEvTac genomic DNA with Pfu Ultra DNA polymerase 
(Stratagene) by PCR (primers for amplifi  cation of the 5′ fragment: forward 
primer 5′-A  A  C  A  C  T  C  G  A  G  A  T  A  C  T  T  G  C  A  G  C  A  A  C  A  C  A  G  T  T  T  G  A  A  C  C-
C  A  C  A  G  C  T  G  -3′ and reverse primer 5′-G  T  G  A  A  T  C  G  A  T  G  C  T  T  A  C  T  A  G  A-
T  G  C  A  G  A  A  G  A  C  T  T  T  T  C  T  T  T  A  T  C  G  T  -3′; primers for amplifi  cation of the 
3′ fragment: forward primer 5′-A  T  G  A  G  C  G  G  C  C  G  C  T  G  C  C  A  A  A  T  T  T  A  T-
G  G  A  G  T  T  T  G  T  G  T  C  T  G  T  C  A  C  T  G  T  G  -3′ and reverse primer 5′-T  T  A  A  C-
C  G  C  G  G  T  T  C  A  G  C  A  A  A  A  A  T  C  T  C  T  G  G  A  C  T  G  A  G  T  C  T  G  A  T  T  -3′). These 
DNA fragments, a neomycin resistance cassette (Neo), and a thymidine ki-
nase cassette (TK) were assembled in a pBluescript II vector (Stratagene) to 
generate the targeting vector. The Neo cassette replaces a fragment from 
intron 4 up to the 5′ end of exon 6, which contains the sequence encoding 
the Zinc-binding motif in the putative active site of ERAP1. Strain 129S6/
SvEvTac-derived embryonic stem (ES) cells (TL-1; obtained from B.   Hogan, 
Duke University Medical Center, Durham, NC) were transfected with 
the KpnI-linearized targeting vector. G418-resistant colonies were selected 
and isolated as described previously (32). Genomic DNA from individual 
clones was digested with EcoRV and hybridized with 5′- and 3′-fl  anking 
probes (Fig. 1 A), which were generated by PCR amplifi  cation (primers for 
amplifi  cation of the 5′ probe: forward primer 5′-T  A  A  G  G  T  T  A  C  A  A  C  T  G-
C  A  T  G  T  C  T  T  C  A  T  A  C  -3′ and reverse primer 5′-A  A  A  C  T  G  T  G  T  T  G  C  T  G  C-
A  A  G  T  A  T  T  C  T  A  C  -3′; primers for amplifi  cation of the 3′ probe: forward 
primer 5′-A  G  T  T  T  C  T  A  C  A  A  A  A  C  A  C  A  A  A  T  G  A  T  C  T  C  C  -3′ and reverse 
primer 5′-C  T  G  T  T  T  T  C  A  G  A  A  A  T  A  A  A  C  C  A  C  A  A  C  T  T  T  -3′). Chimeric 
mice were generated as described previously (32), mated with C57BL/6 
or 129S6/SvEvTac mice, and scored for germline transmission. Mice were 
genotyped by digestion of genomic DNA with EcoRV, followed by hybrid-
ization with one or both probes described above.
Analysis of ERAP1 expression by RT-PCR and immunoblotting. 
For RT-PCR analysis, total RNA treated with RQ1 RNase-free DNase 
(Promega) was subjected to reverse transcription (Advantage RT-for-PCR 
kit; CLONTECH Laboratories, Inc.) and cDNA was amplifi  ed by PCR 
with Taq polymerase (Promega). ERAP1 mRNA was amplifi  ed using for-
ward (5′-C  A  C  T  G  T  G  A  A  G  A  T  G  A  G  T  A  C  C  T  A  C  -3′) and reverse (5′-G  T  G  T-
G  G  A  T  A  C  A  G  G  G  T  G  A  G  A  G  -3′) primers, fl  anking the deleted ERAP1 gene 
fragment, which produces a 551-bp fragment in wild-type animals. β-actin 
mRNA was amplifi  ed as a control using published primers (54).
For Western blot analysis, the rough ER from the liver was isolated as 
described previously (55) and the lumenal fraction was separated on 6% 
SDS-PAGE gels. Immunoblotting was performed with a rabbit antiserum 
raised against a peptide (Q  N  S  D  I  E  S  L  K  A  S  N  G  D  ) from the NH2 terminus of 
mouse ERAP1 (Cocalico Biologicals, Inc.) or with an anti-gp96 polyclonal 
antibody (Santa Cruz Biotechnology, Inc.), and then probed with horserad-
ish peroxidase–conjugated goat anti–rabbit IgG polyclonal antibody (sc-
2054; Santa Cruz Biotechnology, Inc.). Blots were developed using the ECL 
Plus kit (GE Healthcare).
Isolation of fi  broblast cell lines. Ear fi  broblast cells derived from ERAP1−/− 
and ERAP1+/+ animals were immortalized by serial passage in vitro.
Flow cytometry. The following mAbs were used for fl  ow cytometry: anti-
CD4, anti-CD8α, anti-CD8β, anti-Vα2, anti-B220, anti-CD11b, anti-
CD11c, anti–IFN-γ (all from BD Biosciences), anti–H-2Kb (clone Y3; 
American Type Culture Collection [ATCC]), anti–H-2Db (clone B22.249; 
ATCC), anti–Qa-2 (clone 1-2-3; BD Biosciences), anti–Qa-1b (clone 
6A8.6F10.1A6; BD Biosciences), and an antibody (25-D1.16) specifi  c for 
H-2Kb combined with OVA257–264 (provided by A. Porgador [Ben Gurion 
University of the Negev, Beer Sheva, Israel] via L. Pease [Mayo Clinic Col-
lege of Medicine, Rochester, MN];  <CIT>reference 56 </CIT>). Cell suspensions from 
various tissues were prepared according to standard procedures. In some ex-
periments cells were treated with OVA protein, synthetic peptides, recombi-
nant mouse IFN-γ (BD Biosciences), Con A (Calbiochem), or brefeldin A 
(Sigma-Aldrich) before staining. Cells were stained by incubation with anti-
body at 4°C for 1 h followed by three washes in cold PBS supplemented with 
1% fetal calf serum and 0.05% NaN3. For unconjugated primary antibodies, 
the samples were then incubated with a fl  uorescently labeled secondary anti-
body and washed three times. After the fi  nal wash, cells were analyzed using 
a FACSCalibur Flow System (Becton Dickinson) and data were analyzed us-
ing FlowJo software (TreeStar). Dead cells were excluded from the analysis 
based on their forward and sideway light scattering properties.
MHC class I maturation and thermostability assays. MHC class I mat-
uration was examined with a modifi  ed pulse-chase and immunoprecipitation 
procedure (32). Con A–induced T cell lymphoblasts were starved for 1 h in 
methionine/cysteine-free RPMI 1640 medium (Mediatech) at 107 cells/ml, 
and then pulsed with 500 μCi/ml of a [35S]methionine/cysteine mix (MP 
Biomedicals, Inc.) for 10 min at 37°C. After removal of one seventh of the 
cells for the 0 time point, the remaining cells were washed with complete 
RPMI 1640 medium supplemented with 10% fetal calf serum and 1 mM 
methionine and 1 mM cysteine, and further incubated in the same medium 
at 37°C. Cell aliquots were removed at diff  erent time points, spun through 
cold PBS, and stored at −20°C. Cells were lysed in 50 mM Tris-Cl, pH 7.4, 
5 mM MgCl2, 0.5% NP-40 (Fluka), and 1 mM PMSF (Sigma-Aldrich). After 
removal of insoluble materials, the lysates were precleared with normal mouse 
serum and immunoprecipitated with conformation-dependent anti–H-2Kb 
(Y3) and anti–H-2Db (B22.249) antibodies. Immunoprecipitates were treated 
with Endo H (New England Biolabs, Inc.) at 37°C for 1 h before separation 
by SDS-PAGE. Precipitates were visualized by phosphorimaging and band 
intensities were quantifi  ed with ImageQuant software (Applied Biosystems).
The thermostability of MHC class I complexes in cell extracts was ex-
amined as described previously (32, 35). Con A–induced T cell lymphoblasts 
were labeled with [35S]methionine/cysteine as described above for 1 h, and 
then washed with RPMI 1640 medium supplemented with 10% fetal calf 
serum and 1 mM methionine and 1 mM cysteine, and further incubated in 
the same medium for 2 h at 37°C. Cell lysates, generated as described above, 
were precleared with normal mouse serum, divided into six parts, and incu-
bated at either 4, 15, 26, 37, 42, or 50°C for 1 h. MHC class I complexes 
were then precipitated with conformation-dependent anti–H-2Kb (Y3) or 
anti–H-2Db (B22.249) antibodies at 4°C. Immunoprecipitates were treated 
with Endo H at 37°C for 1 h before separation by SDS-PAGE.
Thermostability of surface class I molecules was examined by culturing 
splenocytes with 10 μg/ml brefeldin A and staining samples after diff  erent 
time points with conformation-dependent anti–H-2Kb (Y3) or anti–H-2Db 
(B22.249) antibodies followed by fl  ow cytometry. Data are plotted as the rel-
ative amount of class I expression with the 0 time point indicated as 100%.
In vitro antigen processing and presentation assays. To evaluate the 
presentation of minor H antigens, spleen cells from male ERAP1+/+ or 
ERAP1−/− mice on a homogeneous 129S6/SvEvTac background were used 
as stimulators for activation of minor H antigen-specifi   c CTL clones, as 
  described previously (38). The following CTL clones were used: SP/H60 and 
B6-1/H60, specifi  c for H60 presented by H-2Kb; B10/21M-9 and B10/21M-
11, specifi  c for H4b presented by H-2Kb; B/NX-3, specifi  c for H13b presented 
by H-2Db; CTL-10, specifi  c for HY presented by H-2Db; and 21M/RC6, 
specifi  c for H4a presented by H-2Kb (36–38). Spleen cells from female C57BL/6 
mice were used as a control. Stimulators (1–10 × 105 cells/well) and responders 
(106 cells/well) were cocultured for 1 h, after which 10 μg/ml brefeldin A was 
added to the medium and cells were incubated for an additional 5 h. Cells were 
then surface stained with anti-CD8α mAb, washed, permeabilized with the 
Cytofi  x/Cytoperm kit (BD Biosciences), stained with anti–IFN-γ, and ana-
lyzed by fl  ow cytometry. Data are plotted as percentage CD8+IFN-γ+ cells 
and normalized to the response against ERAP1+/+ cells.
The anti–Qa-1b-specifi  c CTL clones (obtained from C. Aldrich [Indi-
ana University School of Medicine, Evansville, IN], J. Forman [University 
of Texas Southwestern Medical Center, Dallas, TX], and M. Soloski [Johns 
Hopkins University, Baltimore, MD]) were generated from B6.Tlaa (H-2b 
and Qa-1a) anti-C57BL/6 (H-2b and Qa-1b) or B10.BR (H-2k and Qa-1a) 
anti-C3H/HeJ (H-2k and Qa-1b) mixed lymphocyte cultures (47, 57). 658  ERAP1 MUTANT MICE | Yan et al.
  Cytotoxic activity was measured in a standard 4-h 51Cr-release assay (32) us-
ing Con A–activated lymphoblast target cells. As a control, cells were incu-
bated with 100 μM Qdm peptide (AMAPRTLLL; Biosynthesis) during 
labeling. Results are presented as percentage of specifi  c lysis: [(sample release − 
spontaneous release)/(maximal release − spontaneous release)] × 100.
Presentation of OVA antigens was tested by the loading of bone mar-
row–derived DCs, generated as described previously (58), or LPS-activated 
splenocytes with OVA by osmotic shock, as described previously (59). In 
brief,  1.5 × 108 cells were incubated in 1 ml of hypertonic medium (0.5 M 
sucrose, 10% wt/vol PEG 1000, and 10 mM Hepes in RPMI 1640, pH 7.2) 
containing 10 mg/ml OVA (Sigma-Aldrich) for 10 min at 37°C. 13 ml of 
prewarmed hypotonic medium (40% H2O, 60% RPMI 1640) was added and 
the cells were incubated for an additional 2 min at 37°C. The cells were then 
centrifuged, washed twice with complete medium, and resuspended in the 
same medium. One third of the cells was removed immediately at the 0 time 
point. The remaining cells were further incubated in the same medium at 
37°C for 2 or 5 h. Cells loaded with 1 μM OVA257–264 peptide (SIINFEKL; 
Biosynthesis) were cultured for 5 h and used as a positive control. Cell surface 
expression of H-2Kb/SIINFEKL was examined by fl  ow cytometry with the 
25-D1.16 mAb. Alternatively, OVA-loaded cells (1–2 × 106) were cultured 
with 5 × 105 B3Z hybridoma cells (obtained from N. Shastri, University of 
California, Berkeley, CA;  <CIT>reference 60 </CIT>) overnight and IL-2 in the supernatant 
was measured by ELISA. For presentation of bacterial-encoded OVA, we in-
fected thioglycolate-elicited peritoneal macrophages (2 × 106 cells) with a re-
combinant strain of Listeria monocytogenes expressing OVA (2 × 108 CFU; 
obtained from H. Shen, University of Pennsylvania School of Medicine, Phil-
adelphia, PA) in PBS for 30 min. After infection, macrophages were recov-
ered by incubation with 10 mM EDTA in PBS for 1 h. 5 × 104 cells were 
then cocultured with 2 × 105 nonadherent cells from the spleen and lymph 
nodes of OT-1TgRAG1−/− mice for 24 h, and IL-2 in the supernatant was as-
sayed by ELISA. In the cross-presentation assay, splenic DCs were incubated 
with 1.5 μm latex beads (Polyscience), coated with BSA or OVA by passive 
adsorption (incubation with beads at 10 mg/ml in 0.1 M borate buff  er for 48 h 
at 4°C, followed by extensive washes) for 48 h, and then cultured with non-
adherent splenocytes from OT-1TgRAG1−/− mice for 24 h, after which the 
culture supernatant was collected and analyzed for IL-2 content by ELISA.
Presentation of LCMV antigens was determined by infection of bone mar-
row–derived or splenic DCs with the Armstrong strain (obtained from R. Brut-
kiewicz, Indiana University School of Medicine, Indianapolis, IN) at 1 PFU/cell. 
Cells were then cocultured with nonadherent splenocytes from P14TgRAG2−/− 
mice for 24 h, and IL-2 in the supernatant was determined by ELISA.
CD8+ T cell responses. For measurement of OVA-specifi  c CD8+ T cell 
responses, splenocytes from TAP1−/− mice were loaded with 10 mg/ml 
OVA by osmotic shock as described above, and 2 × 107 cells were injected 
into ERAP1−/− or ERAP1+/+ mice. 7 d later, mice were killed, splenocytes 
were cultured with 1 μM OVA257–264 peptide for 6 h, and intracellular pro-
duction of IFN-γ by CD8+ T cells was detected by fl  ow cytometry.
To determine immune responses to infl  uenza virus, mice were infected 
intranasally with 2.5 × 103 PFU of PR8 virus (obtained from H.-G. Ljung-
gren, Karolinska Institute, Stockholm, Sweden). Mediastinal lymph nodes 
from infected mice were harvested 10 d later, and cells were cultured in the 
absence or presence (1 μM) of synthetic versions of the H-2Db–restricted 
peptide epitopes NP366–374 (ASNENMETM), PA224–233 (S  S  L  E  N  F  R  A  Y  V  ), 
or PB1F262–70 (LSLRNPILV), and the H-2Kb–restricted peptide epitopes 
NS2114–121 (RTFSFQLI) or PB2198–206 (ISPLMVAYM). 6 h later, IFN-γ 
production by CD8+ T cells was determined by fl  ow cytometry.
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